NovoCure Limited
15.63USD
-1.2200 (-7.24%)
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $-0.24▲ | $-0.33 | 5 | 1 |
| Next quarter | $-0.25▲ | $-0.32 | 5 | 1 |
| Current year | $-1.25▲ | $-1.59 | 6 | 0 |
| Next year | $-0.82▲ | $-1.17 | 5 | 1 |
Beat in 3 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $-0.33 | $-0.13 | +0.20 (+60.8%) |
| 2026-03-31 | $-0.51 | $-0.62 | -0.11 (-20.9%) |
| 2025-12-31 | $-0.41 | $-0.22 | +0.19 (+46.5%) |
| 2025-09-30 | $-0.42 | $-0.33 | +0.09 (+21.4%) |
123 ratings from 17 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Wedbush | Maintained | Neutral | $18 $20 | Jul 24, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $46 $52 | Jul 23, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $48 $46 | Jun 18, 2026 |
| Wells Fargo | Maintained | Equal-Weight | $13.5 $17 | May 4, 2026 |
| Evercore ISI Group | Maintained | Outperform | $16 $20 | May 1, 2026 |
| Wedbush | Reiterated | Neutral | $18 | Apr 16, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $47 $49 | Feb 26, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $39 $47 | Feb 12, 2026 |
| Wedbush | Reiterated | Neutral | $18 | Jan 15, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $42 $39 | Jan 13, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $38 $42 | Oct 30, 2025 |
| JP Morgan | Maintained | Neutral | $25 $23 | Oct 27, 2025 |
| Wells Fargo | Downgraded from Overweight | Equal-Weight | $40 $14.5 | Jul 25, 2025 |
| Ladenburg Thalmann | Initiated | Buy | $30 | Jul 8, 2025 |
| Piper Sandler | Reiterated | Overweight | $34 | Jun 27, 2025 |
| Piper Sandler | Maintained | Overweight | $42 $34 | Apr 23, 2025 |
| Wedbush | Maintained | Neutral | $29 $27 | Apr 16, 2025 |
| JP Morgan | Maintained | Neutral | $29 $28 | Apr 10, 2025 |
| HC Wainwright & Co. | Reiterated | Buy | $38 | Jan 14, 2025 |
| Piper Sandler | Maintained | Overweight | $28 $42 | Dec 13, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $30 $38 | Dec 3, 2024 |
| HC Wainwright & Co. | Reiterated | Buy | $30 $38 | Dec 2, 2024 |
| Evercore ISI Group | Upgraded from In-Line | Outperform | $18 $30 | Dec 2, 2024 |
| HC Wainwright & Co. | Reiterated | Buy | $30 | Nov 21, 2024 |
| HC Wainwright & Co. | Reiterated | Buy | $30 | Oct 31, 2024 |
99 filings from 18 insiders · 13 buy / 8 sell over 6m
Officers and directors of NVCR, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| BEN ARYE BARAKGeneral Counsel | Grant | 1.3k | $15.15 | $20k | Jun 30, 2026 |
| PURI MICHAL NATHOfficer | Grant | 1.9k | $15.15 | $29k | Jun 30, 2026 |
| DANZIGER ASAFDirector | Grant | 268 | $15.15 | $4k | Jun 30, 2026 |
| LEONARD FRANCIS XAVIER IIChief Executive Officer | Grant | 1.9k | $15.15 | $29k | Jun 30, 2026 |
| LEONARD FRANCIS XAVIER IIChief Executive Officer | Sell | 34.3k | $17.93 | $615k | Jun 4, 2026 |
| OCEAN ALLYSON JDirector | Grant | 11.6k | — | — | Jun 3, 2026 |
| STAFFORD KRISTINDirector | Grant | 11.6k | — | — | Jun 3, 2026 |
| HILLEMAN JERYL LDirector | Grant | 11.6k | — | — | Jun 3, 2026 |
| LEUNG KINYIP GABRIELDirector | Grant | 11.6k | — | — | Jun 3, 2026 |
| HUNG DAVID TDirector | Grant | 11.6k | — | — | Jun 3, 2026 |
| VERNON WILLIAM ANTHONYDirector | Grant | 11.6k | — | — | Jun 3, 2026 |
| SCANNELL TIMOTHY J.Director | Grant | 11.6k | — | — | Jun 3, 2026 |
| MADDEN MARTIN JDirector | Grant | 11.6k | — | — | Jun 3, 2026 |
| HILLEMAN JERYL LDirector | Sell | 2.9k | $15.77 | $46k | Jun 2, 2026 |
| LEUNG KINYIP GABRIELDirector | Sell | 2.9k | $15.77 | $46k | Jun 2, 2026 |
| HUNG DAVID TDirector | Sell | 2.9k | $15.77 | $46k | Jun 2, 2026 |
| VERNON WILLIAM ANTHONYDirector | Sell | 2.9k | $15.77 | $46k | Jun 2, 2026 |
| SCANNELL TIMOTHY J.Director | Sell | 2.9k | $15.77 | $46k | Jun 2, 2026 |
| OCEAN ALLYSON JDirector | Sell | 2.9k | $15.77 | $46k | Jun 2, 2026 |
| STAFFORD KRISTINDirector | Sell | 2.9k | $15.77 | $46k | Jun 2, 2026 |
No analyst notes on NVCR yet.
Analyst Ratings
7 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 1 | 3 | 3 | 0 | 0 | Buy2.29 |
| 1 mo ago | 1 | 3 | 3 | 0 | 0 | Buy2.29 |
| 2 mo ago | 1 | 3 | 3 | 0 | 0 | Buy2.29 |
| 3 mo ago | 1 | 4 | 2 | 0 | 0 | Buy2.14 |